SCHEMBL12763919

SCHEMBL12763919

COc1ccc(Cc2cnc(Oc3ccc(N(C(=O)[C@H]4CC[C@H](C)CC4)C(C)C)c(C(=O)O)c3)c(C(F)(F)F)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F3 P13726 3/20 0.34
▸ F2 P00734 2/20 0.34
▸ BRAF P15056 3/20 0.33
▸ KDR P35968 2/20 0.33
▸ LMNA P02545 1/20 0.32
▸ NR1H4 Q96RI1 1/20 0.32
▸ PTGDR2 Q9Y5Y4 2/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CNR1 P21554 1/20 0.31
▸ CNR2 P34972 1/20 0.31
▸ CSF1R P07333 1/20 0.31
▸ TRPM8 Q7Z2W7 1/20 0.31
▸ KDM5A P29375 1/20 0.31
▸ KDM5B Q9UGL1 1/20 0.31
▸ F10 P00742 1/20 0.31
▸ F7 P08709 1/20 0.31
▸ RAF1 P04049 1/20 0.31
▸ RIPK1 Q13546 1/20 0.31
▸ NR1H2 P55055 1/20 0.30
▸ NR1H3 Q13133 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12763896 0.90 TRPM8 (0.33) F3F2BRAFKDRNR1H4
SCHEMBL12763916 0.88 NR1H2 (0.32) F3F2BRAFKDRTRPM8
SCHEMBL12763889 0.87 PDE4B (0.32) BRAFKDR
SCHEMBL13044897 0.86 BRAF (0.30) BRAFKDR
SCHEMBL12763835 0.85 KDR (0.33) F3F2BRAFKDR
SCHEMBL12763914 0.85 TRPM8 (0.31) F3BRAFKDRNR1H4TRPM8
SCHEMBL12763911 0.85 CSF1R (0.33) F3F2BRAFKDRCSF1R
SCHEMBL12763906 0.85 BRAF (0.31) BRAFKDRTRPM8RAF1
SCHEMBL12763876 0.85 SRD5A2 (0.34) F3F2BRAFKDR
SCHEMBL12763894 0.85 CACNA1G (0.33) F3F2BRAFKDRNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897622-B2 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-01 — — US disclosed
US-7897622-B2 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-01 — — US disclosed
WO-2008019477-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-21 — — WO disclosed
US-20080045516-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-21 — — US disclosed
US-20080045516-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045516-A1 Viral Polymerase Inhibitors POLR2A, POLR2H, POLR2E F3 212/4885F2 287/4885BRAF 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback